SCHEMBL1745405

SCHEMBL1745405

Cc1cc(OCc2cccc(-c3ccccc3)c2)ccc1CCC(=O)O

nearest known ligand 0.83

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 19/20 0.83
FFAR4 Q5NUL3 3/20 0.70
AKR1B1 P15121 1/20 0.70
PTGER4 P35408 1/20 0.61
PTGER3 P43115 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1745115 0.91 FFAR1 (1.00) FFAR1FFAR4
SCHEMBL7102537 0.90 FFAR1 (0.74) FFAR1FFAR4PTGER4PTGER3
SCHEMBL1746661 0.90 FFAR1 (0.68) FFAR1FFAR4AKR1B1PTGER4PTGER3
SCHEMBL4835765 0.90 FFAR1 (0.71) FFAR1FFAR4AKR1B1
SCHEMBL16354338 0.89 FFAR1 (0.77) FFAR1FFAR4AKR1B1
SCHEMBL16354329 0.88 FFAR1 (0.72) FFAR1FFAR4AKR1B1
SCHEMBL16354326 0.88 FFAR1 (0.74) FFAR1FFAR4AKR1B1
SCHEMBL2000659 0.87 FFAR1 (0.71) FFAR1FFAR4
SCHEMBL1999731 0.87 FFAR1 (0.71) FFAR1FFAR4AKR1B1PTGER4PTGER3
SCHEMBL1746778 0.86 FFAR1 (0.80) FFAR1FFAR4AKR1B1PTGER4PTGER3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR1 33/4885FFAR4 44/4885AKR1B1 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.